Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature
N Kremer, I Snast, ES Cohen, E Hodak… - American Journal of …, 2019 - Springer
Background Bullous pemphigoid (BP) is the most common autoimmune blistering skin
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …
Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.
N Kremer, I Snast, ES Cohen, E Hodak… - American Journal of …, 2019 - europepmc.org
Background Bullous pemphigoid (BP) is the most common autoimmune blistering skin
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …
[引用][C] Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature
N Kremer, I Snast, ES Cohen, E Hodak… - American Journal of …, 2018 - cir.nii.ac.jp
Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review
of the Literature | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ …
of the Literature | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ …
Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature
N Kremer, I Snast, ES Cohen… - … journal of clinical …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Bullous pemphigoid (BP) is the most common autoimmune blistering skin
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …
[PDF][PDF] Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature
N Kremer, I Snast, ES Cohen, E Hodak, D Mimouni… - academia.edu
* A-prospective, B-retrospective, C-case reports and case series** 1-375 mg/m2 weekly; 2-
1000 every 2 weeks or 500 weekly; 3-375 every 2-4 weeks*** CR-complete response, PR …
1000 every 2 weeks or 500 weekly; 3-375 every 2-4 weeks*** CR-complete response, PR …
[PDF][PDF] Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature
N Kremer, I Snast, ES Cohen, E Hodak, D Mimouni… - 2018 - researchgate.net
Background Bullous pemphigoid (BP) is the most common autoimmune blistering skin
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …
disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; …